跳至主要内容
临床试验/NCT04615052
NCT04615052Unknown不适用

Home-based Exercise Training in COVID-19 Survivors: a Randomized Controlled Trial

University of Sao Paulo2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2020年9月26日最近更新:
适应症

试验速览

阶段
不适用
入组人数
50
试验地点
2
主要终点
Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at 16 weeks.

研究概览

简要总结

The physical inactivity promoted by the patient's hospitalization, including those infected with the coronavirus, can lead to an important health impairment, including atrophy and loss of muscle function. Thus, a prospective study will be conducted to assess the effect of a home-based exercise training program on health outcomes and quality of life in COVID-19 survivors.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with COVID-19
  • Positive RT-PCR test and/or serology assay to detect IgG against SARS-CoV-2 in addition to acute symptomatology compatible with the disease
  • Admitted in intensive care unit

排除标准

  • Cardiovascular disease
  • Resting dyspnea
  • Acute pulmonary embolism or pulmonary infarction
  • Deep venous thromboembolism
  • Uncontrolled visual or vestibular disorders
  • Pregnancy
  • Uncontrolled resting tachycardia
  • Uncontrolled hypertension
  • Uncontrolled Type II diabetes
  • Acute infections
  • Neurological disorders
  • Patients with chronic kidney disease who are in need of hemodialysis
  • Recent malignant neoplasm (<5 years)
  • Autoimmune diseases
  • Complex ventricular arrhythmias, atrial fibrillation or complete heart block
  • Transplant patients
  • Any physical disabilities that could hamper physical testing and exercise program

结局指标

主要结局

Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at 16 weeks.

时间窗: Baseline and 16 weeks.

Higher score means better outcome.

次要结局

  • Change from baseline on physical activity levels evaluated by the International Physical Activity Questionnaire at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on lipid profile at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on inflammatory cytokine IL-6 at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on lean body mass assessed by Dual-energy absorptiometry at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on muscular function assessed by Timed-Up and Go Test at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on fatigue assessed by Chalder scale at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on inflammatory cytokine IL-10 at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on fatigue evaluated by the fatigue severity scale at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on insulin sensitivity at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on fatigue evaluated by the fatigue severity scale at one year.(Baseline and one year.)
  • Change from baseline on inflammatory cytokine IL-1ra at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on C-reactive Protein at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on cardiopulmonary fitness assessed by a maximal exercise test at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on body weight at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on muscular function assessed by Timed-Stand Test at 16 weesks.(Baseline and 16 weeks.)
  • Change from baseline on inflammatory cytokine IL-1 at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on inflammatory cytokine TNF-alpha at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on waist circumference at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on hip circumference at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on depression symptoms assessed by Back Scale at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on functional status assessed by Post-COVID-19 Functional Status (PCFS) Scale at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on cardiopulmonary fitness assessed by a maximal exercise test at one year.(Baseline and one year.)
  • Change from baseline on Creatine Kinase at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline body fat assessed by Dual-energy absorptiometry at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on muscular strength assessed by handgrip test at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on anxiety symptoms assessed by Back Scale at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on resting blood pressure assessed by an automated device at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on inspiratory muscular strength assessed by power breathe at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on fatigue assessed by Chalder scale at one year.(Baseline and one year.)
  • Change from baseline on functional status assessed by Post-COVID-19 Functional Status (PCFS) Scale at one year.(Baseline and one year.)
  • Change from baseline on muscular strength assessed by handgrip test at one year.(Baseline and one year.)
  • Change from baseline on heart rate variability assessed by heart rate monitor at 16 weeks.(Baseline and 16 weeks.)
  • Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at one year.(Baseline and one year.)
  • Change from baseline on muscular function assessed by Timed-Stand Test at one year.(Baseline and one year.)
  • Change from baseline on muscular function assessed by Timed-Up and Go Test at one year.(Baseline and one year.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Bruno Gualano

Professor

University of Sao Paulo

研究点 (2)

Loading locations...

相似试验

Home-based Exercise in COVID-19 Survivors | 临床试验